Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Melanoma 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × ADI PEG20 × Clear all
NCT00520299 2022-10-25

Study of ADI-PEG 20 in Patients With Advanced Melanoma

Ludwig Institute for Cancer Research

Phase 1/2 Completed
31 enrolled 16 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT02102022 2022-04-25

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Polaris Group

Phase 1/2 Terminated
140 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡